Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference

On October 1, 2019 Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, reported that Reenie McCarthy, Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 5:20 p.m. ET in New York (Press release, Stealth Biologics, OCT 1, 2019, View Source [SID1234540002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors & News section of Stealth’s website at https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth’s website for 30 days following the event.

Immunicom Secures an Additional $1.85 Million Bringing its Series B Funding to $12.85 Million

On October 1, 2019 Immunicom, Inc., a medical technology company reported that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, gained an additional $1.85 million towards its Series B investment round on September 9th (Press release, Immunicom, OCT 1, 2019, View Source [SID1234540001]). This increases Immunicom’s overall capital raised to $21.85 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunicom has also hired Raju Chauhan as Vice President of Program Management to provide guidance and oversight to both internal and customer facing initiatives. "We are very fortunate to add Raju to Immunicom’s growing team," said Amir Jafri, the company’s Founder and CEO. "With Raju on our team we will be more proficient in achieving our fast-paced global business deals and groundbreaking research goals to accelerate bringing Immunopheresis to the world."

Raju has over 30 years of experience working in the technology development and managing teams across the globe with a proven record of creating and delivering, innovative, cost-effective solutions for mission-critical business problems. He has been an integral part of managing projects for several fortune 50 companies as well as healthcare space. At Cardinal Health, Raju managed teams spread across several locations in USA. Raju has also managed and worked with many different teams in several countries including Canada, China, India, and Ukraine. Raju has worked in many different industries including Medical Device Manufacturers, Healthcare, Oil and Gas, Software, Telecommunications, Food and Beverages, Airlines, Credit Bureaus, Background Checks, Real Estate, Professional Services and Utilities.

Raju received his Master of Computer Science degree from Mississippi State University.

AIVITA Biomedical to Present at Meeting on the Mesa and Other Investor, Oncology and Regenerative Medicine Conferences in October

On October 1, 2019 AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, reported that it will be presenting at the following investor, oncology and regenerative medicine conferences in October (Press release, AIVITA Biomedical, OCT 1, 2019, View Source [SID1234540000]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell & Gene Meeting on the Mesa
Company Presentation
Time: October 2, 11:00 AM PST
Location: Park Hyatt Aviara Resort Golf Club & Spa, Cognate in the Bioservices Ballroom, Carlsbad, CA

World Immunotherapy Congress
Keynote Title: Enhancing patient responses with autologous cancer stem cell vaccine in combination with checkpoint inhibitors
Time: October 16, 9:25 AM CET
Location: Congress Centre Basel, Basel, Switzerland

BIO Investor Forum
Company Presentation
Time: October 23, 10:15 AM PST
Location: Elizabethan A, The Westin St. Francis, San Francisco, CA

World Vaccine Congress
Talk Title: Autologous Cancer Stem Cell Vaccines for Solid Tumor Cancers
When: October 29, 3:45 PM CET
Location: Palau de Congressos de Catalunya, Barcelona, Spain

Amyris Provides Highlights of First Half 2019 Financial Results

On October 1, 2019 Amyris, Inc. (Nasdaq: AMRS) reported highlights of its business and financial results for the first half of 2019 ended June 30, 2019, which it will review during a conference call after market close on Wednesday, October 2, 2019 (Press release, Amyris Biotechnologies, OCT 1, 2019, View Source [SID1234539999]). The company also noted that it is has filed its 2018 Form 10-K and expects to file its Form 10-Qs for the first and second quarters of 2019 before the conference call on Wednesday. As a result of completing these filings, the company believes that it will have filed all of its delinquent SEC filings and be back in compliance with Nasdaq listing rules.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First-Half 2019 Financial Results and Recent Business Highlights

First-half 2019 GAAP revenue of $77.1 million with very strong gross margin compared to total first-half 2018 GAAP revenue of $32.9 million
Successful launch of Pipette baby care brand raising the bar for clean and safe baby care products
International expansion of Biossance, one of the fastest growing clean beauty skincare brands in the US, gets a strong start upon entry into Australian and New Zealand markets
Expansion of ADL Bionatur Solutions (ADL) manufacturing agreement and execution of strategic supply agreement with Raízen, the largest sugar producer in the world, to provide additional, cost-effective manufacturing capacity to meet growth demand
Appointment of two new board members with significant experience in building high growth product and consumer companies ‒ Jim McCann, founder and chairman of 1-800-Flowers, and Lisa Qi, founder and CEO of Daling Family e-commerce platform in China
Receipt of first milestone payment of $10 million in March 2019 for successful cannabinoid (CBD) development; good progress being made toward second major milestone
"We are pleased with our financial results for the first-half of 2019," said John Melo, Amyris President and CEO. "Our teams have delivered higher volumes to support stronger demand this year and in the second half they are continuing at record levels. We remain confident that we will exceed our revenue goal for 2019. Our $300 million cannabinoid development collaboration is also exceeding our expectations. We are now on track to be the first company to produce multiple cannabinoids at commercial scale that are fermentation derived in 2020."

The company will hold its conference call to discuss financial results and business highlights for the first half of 2019, as well as provide an update on the company’s business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, October 2, 2019. The company will not be issuing a customary earnings release on its financial results prior to the call, as the company expects that the financial results for the first and second quarters of 2019 will have been fully disclosed via the filing of required Form 10-Qs.

Conference Call:
Wednesday, October 2, 2019, 4:30 p.m. ET/1:30 p.m. PT

Dial-in Number:
(877) 870-4263 (U.S. & International)

Participants should ask to be joined to the Amyris, Inc. call.

Audio Webcast:
A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: View Source A replay of the webcast will be available on the Investor Relations section of the company’s website approximately two hours after the conclusion of the call.

Boston Scientific Announces Conference Call Discussing Third Quarter 2019 Financial Results

On October 1, 2019 Boston Scientific Corporation (NYSE: BSX) reported that it will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2019 on Wednesday, October 23, 2019 at 8:00 a.m. EDT (Press release, Boston Scientific, OCT 1, 2019, View Source [SID1234539998]). The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on Wednesday, October 23, 2019, prior to the conference call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call will be available on the Investor Relations section of the website at investors.bostonscientific.com.

A replay of the webcast will be archived and available at investors.bostonscientific.com beginning approximately one hour following the completion of the meeting.